BMEZ BlackRock Health Sciences Term Trust Insider Trading

Saba Capital (10% owner) buys 64,716 shares at $15.81 across 2 transactions; 20.75M shares held post-trade.

Saba Capital Management filed two open-market purchases at BlackRock Health Sciences Term Trust on consecutive days (2024-10-15 and 2024-10-16), acquiring 34,921 shares and 29,795 shares respectively at a blended average price of $15.81, totaling $1,023,159.96 for 64,716 shares. The purchases represent a 0.3% increase to the insider's existing 20.69M-share position, bringing holdings to 20.75M shares. At the time of purchase, the stock traded near the midpoint of its 52-week range ($13.02–$16.54), with the transaction price $15.81 sitting approximately 0.9% above the current price of $15.67. The decision to buy across two consecutive trading days, combined with the modest position increment, reflects opportunistic accumulation by a controlling shareholder rather than a singular conviction signal.

Saba Capital Management (10% owner) bought 15,281 shares of BlackRock Health Sciences Term Trust (BMEZ) at $15.87 on 2024-10-14 for $242,509.47.

Saba Capital Management, a 10% shareholder, purchased 15,281 shares at $15.87, a small incremental addition to holdings that increased its position from 20,670,916 to 20,686,197 shares (+0.1%). The transaction occurred when BMEZ was trading at $15.87, near the upper end of its 52-week range of $13.02–$16.54, and well above the current price of $15.80. Across all tickers in Saba's open-market history, the insider has executed 10 prior buys and 10 prior sells with no pattern of well-timed buys at the 90-day measurement window. This purchase represents a discrete addition to an already substantial position but does not constitute a material shift in ownership or conviction given the modest +0.1% increase in holdings.

BlackRock executive Accettella buys 1,190 shares of BMEZ at $15.17; holdings rise to 4,069 shares (+41.3%)

Christopher Accettella purchased 1,190 shares of BlackRock Health Sciences Term Trust at $15.17 on January 11, 2024, increasing his holdings by 41.3% to 4,069 shares. The transaction occurred near the midpoint of the 52-week range ($13.02–$16.54) and modestly below the current price of $15.89. This is a routine buy transaction by an insider in a closed-end fund; the scale and holding-size increase suggest a discretionary purchase, though without flagging information, the timing context and strategic reasoning are not discernible from this filing alone.

Saba Capital bought 9,526 shares of BMEZ at $15.79 on 2024-10-01; now holds 20.67M shares (20.67M post-transaction).

Saba Capital Management, a 10% owner, purchased 9,526 shares at $15.79, adding to a substantial base of 20.67M shares. This represents a routine addition to an already dominant position. The transaction occurred as BMEZ traded near the lower end of its 52-week range ($13.02–$16.54), down 4.7% from the 52-week high. Notably, Saba has executed four additional purchases at this ticker within the prior four trading days (2024-09-25 through 2024-09-30), signaling sustained engagement with the position during a period of modest price pressure. The cross-ticker track record shows 15 prior buys against 5 prior sells, but none of the same-ticker purchases yet have measurable 90-day outcomes.

Saba Capital (10% owner) bought 8,012 shares of BMEZ at $15.84 on 2024-09-30; part of pattern of 4 consecutive daily purchases in late September.

Saba Capital Management purchased 8,012 shares at $15.84, adding to holdings that now total 20,661,390 shares post-transaction. This purchase is part of a concentrated buying period: the FACTS disclose four prior trades at BMEZ within a 6-day window (2024-09-25 through 2024-10-01), all purchases. The current price of $15.89 stands -3.9% from the 52-week high of $16.54 and +4.4% over 90 days. The insider's cross-ticker track record shows 16 prior buys against 4 prior sells, indicating a buy-oriented history. However, across Saba Capital's entire open-market history, 0 of 0 prior buys have been measurable as well-timed at the 90-day mark, and the same-ticker outcomes at BMEZ remain unmeasurable as these recent transactions occurred in late September 2024.

Saba Capital (10% owner) purchases 49,504 shares of BMEZ for $782,788.88 in 2 transactions at $15.81–$15.89

Saba Capital Management, L.P., a 10% owner of BlackRock Health Sciences Term Trust, executed 2 separate purchases totaling 49,504 shares for $782,788.88 on 2024-09-26 and 2024-09-27 at prices ranging from $15.81 to $15.89, bringing post-transaction holdings to 20.65M shares. This represents a 0.2% increase to holdings and follows a pattern of recent acquisition activity at this ticker, with 4 prior trades at BMEZ occurring within days (2024-09-19 through 2024-09-30), suggesting sustained buying interest in the closed-end fund near its current trading level of $15.84. The blended purchase price of $15.81 sits 4.2% below the 52-week high of $16.54, positioning the entry within the fund's upper-half range, though immediate performance on these shares remains unmeasurable given the recent filing date.

Saba Capital (10% owner) bought 300 shares of BMEZ at $15.73 on 2024-09-25; position now 20,603,874 shares.

Saba Capital Management purchased 300 shares of BlackRock Health Sciences Term Trust for $4,719.00, a routine addition to an already substantial 20.60M share position. The transaction occurred at $15.73, near the 52-week midpoint and -4.5% from the 52-week high of $16.54. This represents Saba's fifth consecutive buy at BMEZ within a 7-trading-day window (2024-09-17 through 2024-09-26), though outcomes on these recent trades are not yet measurable at the 30-day and 90-day milestones. Across Saba's broader open-market history, the insider has completed 16 prior buys versus 4 prior sells, establishing a net-long orientation, though ticker-specific timing success rates remain unknown given the recency of these BMEZ purchases.

Saba Capital Management acquired 2,006 shares of BMEZ at $15.98 on 2024-09-23 (20.60M holdings post-trade).

Saba Capital Management, a 10% owner of BlackRock Health Sciences Term Trust, purchased 2,006 shares at $15.98 on 2024-09-23, representing a net addition of 2,006 shares to holdings of 20.60M shares post-transaction. The purchase occurred near the 52-week high ($16.54), with the current price at $15.83 marking a -4.3% decline from that peak. This buy follows two additional purchases by the same insider at BMEZ on 2024-09-19 and 2024-09-18, suggesting a pattern of accumulation within a compressed three-day window, though outcomes on those earlier trades remain unmeasurable. The insider's cross-ticker track record shows 17 prior buys and 3 prior sells across all tickers.

Saba Capital (10% owner) purchased 15,455 shares of BMEZ at $16.14 on 2024-09-19, adding to recent buying activity in the fund.

Saba Capital purchased 15,455 shares at $16.14, representing a +0.1% increase to holdings of 20,601,568 shares post-transaction. The purchase price of $16.14 is 0.7% above the current price of $16.02, and the stock is down 3.1% from its 52-week high of $16.54. This transaction is part of a concentrated buying pattern at this ticker: Saba completed three separate purchases at BMEZ within four trading days (2024-09-17, 2024-09-18, and 2024-09-19), totaling approximately 15,455 shares in this filing alone. Prior outcomes for the same-ticker transactions are not yet measurable. Cross-ticker, the insider's open-market history shows 18 prior buys against 2 prior sells.

Saba Capital purchased 47,682 shares at blended average $15.91, adding 0.2% to 20.59M share position at BMEZ.

Saba Capital Management filed two separate purchases totaling 47,682 shares for $758,547.56 on 2024-09-17 and 2024-09-18, executed at $15.93 and $15.88 respectively (blended average $15.91). This represents a modest 0.2% addition to the firm's 20.59M share position at BlackRock Health Sciences Term Trust. The current price of $16.12 stands 2.5% below the 52-week high of $16.54, and the stock has appreciated 2.9% over 30 days and 7.8% over 90 days. Saba's cross-ticker track record shows 19 prior buys against only 1 prior sell, indicating a net positive orientation toward accumulation, though same-ticker history remains limited with timing outcomes not yet measurable on the recent BMEZ position.